Granzyme B Inhibitor Z-AAD-CH2Cl
目录号 : GC14443
Cell-permeable and irreversible granzyme B inhibitor
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Z-AAD-CH2Cl (Z-AAD-CMK) is a cell-permeable and irreversible inhibitor of granzyme B [1].
Granzyme B is an apoptosis-inducing factor that expressed in natural killer (NK) cells, the granules of cytotoxic lymphocytes (CTLs) and cytotoxic T cells, and plays an important role in inducing inflammation and extracellular matrix remodelling [1].
Z-AAD-CH2Cl (Z-AAD-CMK) is a cell-permeable and irreversible granzyme B inhibitor. In human C-28/12 chondrocytes expressed the surface antigens of NK cells, Z-AAD-CMK dose-dependently inhibited chondrocyte cytotoxicity against K562 cells that was dependent on granzyme B [1]. In the oral squamous cell carcinoma cell line OSC-3, Z-AAD-CMK reduced interleukin-2-activated lymphocytes (LAK cell)-enhanced caspase-3 activity to approximately 70% and inhibited DNA fragmentation by approximately 20% of the control. Z-AAD-CMK also inhibited the increase of reactive oxygen intermediates (ROI) induced by LAK cells to approximately half of the control [2]. In Tc1 cells, Z-AAD-CMK inhibited apoptosis [3].
References:
[1]. Saito S, Murakoshi K, Kotake S, et al. Granzyme B induces apoptosis of chondrocytes with natural killer cell-like cytotoxicity in rheumatoid arthritis. J Rheumatol, 2008, 35(10): 1932-1943.
[2]. Yamamoto T, Yoneda K, Ueta E, et al. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. Eur J Cancer, 2000, 36(15): 2007-2017.
[3]. Gorak-Stolinska P, Truman JP, Kemeny DM, et al. Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNF-alpha. J Leukoc Biol, 2001, 70(5): 756-766.
| Cas No. | SDF | ||
| 化学名 | (Z)-2-((E)-((benzyloxy)(hydroxy)methylene)amino)-N-((Z)-1-((5-chloro-1-methoxy-1,4-dioxopentan-3-yl)imino)-1-hydroxypropan-2-yl)propanimidic acid | ||
| Canonical SMILES | CC(/N=C(O)/C(/N=C(OCC1=CC=CC=C1)\O)C)/C(O)=N/C(C(CCl)=O)CC(OC)=O | ||
| 分子式 | C20H26ClN3O7 | 分子量 | 455.89 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1935 mL | 10.9676 mL | 21.9351 mL |
| 5 mM | 0.4387 mL | 2.1935 mL | 4.387 mL |
| 10 mM | 0.2194 mL | 1.0968 mL | 2.1935 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet